Search Results for: stem cell biotech

Overplaying N=1 in the stem cell therapy world

stem cell therapy, star patient

The regular emails and phone calls I get from patients asking questions about stem cell therapy are a powerful reminder of the fact that research in our field can be very personal. Sometimes individuals who receive experimental stem cell therapy (or other cell therapies) and seem to have a positive outcome can end up becoming …

Overplaying N=1 in the stem cell therapy world Read More »

End of FDA “grace period” impacted perinatal cell therapy biotechs

knot in umbilical cord, perinatal cell therapy

If there’s one area of biologics where the FDA has been consistently busy lately it’s the perinatal cell therapy space. The agency has made it clear in the last year that allogeneic birth-related cell products are often drugs requiring premarket approval. This has mainly manifested at a practical enforcement level. We’ve seen actions taken in …

End of FDA “grace period” impacted perinatal cell therapy biotechs Read More »

Review of Peter Diamandis Fountain Life clinics: more than stem cell hype?

Fountain Life Peter Diamandis featured

Many of you readers know tech guru Peter Diamandis for his great X PRIZE, but he’s also involved in the regenerative medicine world including a new effort called Fountain Life. Teaming up with life coach Tony Robbins and others for Fountain Life raises some red flags for me. What’s in this article Peter Diamandis and …

Review of Peter Diamandis Fountain Life clinics: more than stem cell hype? Read More »

Weekly reads: fibroblasts, cancer stem cells, Parkinson’s

fibroblasts stained

It seems like the field of cell biology has mixed feelings about fibroblasts so I’m going to start off there with the recommended reads. But first, check out our stem cell YouTube channel as we are steadily heading toward 500 subscribers and 30,000 views. Please subscribe. I’ve pasted one of our top videos below, which …

Weekly reads: fibroblasts, cancer stem cells, Parkinson’s Read More »

Biotech California Cultured aims to sell lab-grown chocolate

California Cultured lab-grown chocolate. Pic by Paul Knoepfler.

I’m fascinated by the idea of making food from cells grown in a lab and especially the newest idea of lab-grown chocolate. While lab-grown meat has gotten the most attention, (see my recent post on test-tube meat: Not Old MacDonald’s Farm: is the future lab-grown meat?) I’d say that the coolest application of making food from …

Biotech California Cultured aims to sell lab-grown chocolate Read More »

All about Altos Labs & its $3B cellular rejuvenation push

Altos Labs PIs

I wrote briefly a few months ago about Altos Labs. It’s a new kind of biotech institute that is focused on cellular reprogramming. My original piece was sparked in part by an article around the same time by Antonio Regalado over at MIT Tech Review. He provided some tantalizing details on Altos. Also, I had heard some …

All about Altos Labs & its $3B cellular rejuvenation push Read More »

16 predictions for stem cells & regenerative medicine in 2022

regenerative medicine, stem cells 2021

The last few years in the stem cell and regenerative medicine arena have been complicated in many ways. Variables like surging stem cell clinics and COVID have made predictions harder.  Even so, trying to make predictions is useful and it’s fun to go over past year’s predictions. You can see my scorecard on my 2021 …

16 predictions for stem cells & regenerative medicine in 2022 Read More »

Grading my 21 stem cell & regenerative medicine predictions for 2021

stem-cell-crystal-ball-300x3001

The world of stem cell research and regenerative medicine is unpredictable but it’s fun to be a part of it and try to do predictions. Each year in late December or early January I make prognostications for the coming year for stem cell research and regenerative medicine. I made 21 such predictions for the current …

Grading my 21 stem cell & regenerative medicine predictions for 2021 Read More »

2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best

Mesoblast stock

A quick review of the publicly-traded stem cell stocks I’ve been following in 2021 finds mostly discouraging news, but a few firms relatively outperformed the other publically-traded biotechs. One had some great news today. In this post, I’m doing a brief overview of how things went this year in the regenerative medicine space. I’m going …

2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best Read More »